Dual-dose Aprepitant to Reduce Postoperative Nausea and Vomiting After Laparoscopic Bariatric Surgery.

Phase 4 Terminated 71 enrolled Insel Gruppe AG, University Hospital Bern

RandomizedParallel-groupQuadruple-blindPrevention

Summary

Postoperative nausea and vomiting (PONV) is unpleasant and increases health care costs. Despite modern techniques and prophylaxis, PONV rates remain high after laparoscopic bariatric surgery. We aim to reduce PONV after laparoscopic bariatric surgery using aprepitant with a similar scheme used for emetogenic chemotherapy.

Timeline

Start: 2022-03-17
Primary completion: 2025-02-20
Completion: 2025-02-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aprepitant	Other / unclassified	80 mg	Oral

Indications

No indication recorded.